<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308735</url>
  </required_header>
  <id_info>
    <org_study_id>3948</org_study_id>
    <nct_id>NCT02308735</nct_id>
  </id_info>
  <brief_title>Fatty Acid Ethyl Esters in Meconium of Infants of Diabetic Mothers: a Pilot Trial</brief_title>
  <acronym>FAEE-IDM</acronym>
  <official_title>Fatty Acid Ethyl Esters in Meconium of Infants of Diabetic Mothers: a Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gestational diabetes mellitus (GDM) affects as many as 14% of women in the United States.&#xD;
      Furthermore, the number of pregnant women with pregestational diabetes mellitus (PGDM) is&#xD;
      also increasing, mainly due to an increase in the diagnosis of non-insulin dependent diabetes&#xD;
      mellitus. A recent study demonstrated that 1.3% of pregnancies are now complicated by PGDM&#xD;
      and that PGDM now comprises 21% of the diabetes that complicate gestations, which represents&#xD;
      a two fold increase since 1999. One notable side effect of diabetes is an elevation of&#xD;
      endogenous ethanol production, which in turn may result in a rise in fetal production of&#xD;
      fatty acid ethyl ester (FAEE). FAEE found in meconium have been utilized as a marker of&#xD;
      prenatal ethanol exposure. Therefore, FAEE elevation could call into question maternal claims&#xD;
      of abstinence from alcohol during pregnancy. This study seeks to determine if meconium FAEE&#xD;
      levels in the newborns of abstinent women with various classifications of diabetes mellitus&#xD;
      are increased when compared to non-diabetic, abstaining controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Researchers will approach four groups of pregnant women at 24-26 weeks when they present for&#xD;
      routine obstetrical out-patient appointments:&#xD;
&#xD;
        1. Those with PGDM&#xD;
&#xD;
        2. Those with White's Class A1 GDM&#xD;
&#xD;
        3. Those with White's Class A2 GDM&#xD;
&#xD;
        4. Non-diabetic controls&#xD;
&#xD;
      The medical records of these women will be examined to determine self-reporting of any&#xD;
      alcohol or other drug usage while pregnant; women who report any illicit drug use (or ethanol&#xD;
      use) while pregnant will not be eligible for this study. A routine urine drug screen will&#xD;
      further confirm this finding. Women who have not reported alcohol use during their pregnancy&#xD;
      will be questioned regarding medication usage while pregnant, as some medications do contain&#xD;
      small amounts of ethanol. Women who are judged to have not consumed alcohol during their&#xD;
      pregnancies (intentionally or incidentally) would then be included in the study.&#xD;
&#xD;
      Demographic information about the mother would also be collected (age, parity, length of&#xD;
      pregnancy), as would the mother's most recent glycosylated hemoglobin level; additionally, a&#xD;
      glycosylated hemoglobin level will be drawn on our presumptive controls (to allow for covert&#xD;
      gestational diabetes mellitus). This lab draw would be added to the mother's routine lab&#xD;
      studies and would not require an additional venipuncture.&#xD;
&#xD;
      A second urine drug screen will be performed on the mother upon her admission to the&#xD;
      University of Oklahoma Health Sciences Center for the delivery of her baby. If both screens&#xD;
      are negative and the baby does not meet any of the exclusion criteria, the baby will be&#xD;
      enrolled in the study.&#xD;
&#xD;
      The initial meconium from each baby of the recruited mothers will be gathered. Approximately&#xD;
      1 g of meconium will be collected, frozen, and evaluated for fatty acid ethyl ester analysis&#xD;
      at the United States Drug Testing Laboratories, Inc. We will also be sending a dried blood&#xD;
      spot from the baby which will be collected at the time of the baby's scheduled newborn&#xD;
      screen. This dried blood spot will be evaluated for phosphatidylethanol, an ethanol&#xD;
      by-product.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Technology has advanced beyond the applicability of the study&#xD;
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">September 1, 2017</completion_date>
  <primary_completion_date type="Actual">September 1, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Meconium Fatty Acid Ethyl Ester Concentration</measure>
    <time_frame>Three months</time_frame>
    <description>A measure of ethanol metabolites in the meconium of an infant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phosphatidylethanol Level</measure>
    <time_frame>Three months</time_frame>
    <description>A measure of phosphatidylethanol, an ethanol metabolite, in the cord blood of an infant.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">4</enrollment>
  <condition>Infants of Diabetic Mothers</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A1 IDM</arm_group_label>
    <description>Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2 IDM</arm_group_label>
    <description>Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PGDM - IDM</arm_group_label>
    <description>Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>N/A - No intervention</intervention_name>
    <arm_group_label>A1 IDM</arm_group_label>
    <arm_group_label>A2 IDM</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>PGDM - IDM</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine sample, meconium sample, placental cord blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Teetotaling pregnant women either without a diagnosis of diabetes (controls) or with a&#xD;
             diagnosis of diabetes mellitus (either gestational or pregestational).&#xD;
&#xD;
          2. The liveborn infants resulting from the concurrent pregnancies of the women listed&#xD;
             above.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: (understood to include only abstemious women)&#xD;
&#xD;
          1. . Pregnant women expected to deliver between 37 and 41 weeks gestation (controls), and&#xD;
             their babies&#xD;
&#xD;
          2. . Pregnant women expected to deliver between 37 and 41 weeks gestation who have class&#xD;
             A1 diabetes mellitus, and their babies&#xD;
&#xD;
          3. . Pregnant women expected to deliver between 37 and 41 weeks gestation who have class&#xD;
             A2 diabetes mellitus, and their babies&#xD;
&#xD;
          4. . Pregnant women expected to deliver between 37 and 41 weeks gestation who were&#xD;
             diagnosed with diabetes mellitus prior to their pregnancy, and their babies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. . Mothers who self-reported any alcohol or any illicit drug use during their pregnancy&#xD;
             (and their babies)&#xD;
&#xD;
          2. . Mothers who had a positive drug screen at any point during their pregnancy (and&#xD;
             their babies)&#xD;
&#xD;
          3. . Babies whose mothers suffered a placental abruption during their pregnancy.&#xD;
&#xD;
          4. . Babies whose mothers had inadequate prenatal care (defined as &lt;3 prenatal clinic&#xD;
             visits prior to admission for delivery)&#xD;
&#xD;
          5. . Non-English-speaking mothers&#xD;
&#xD;
          6. . Babies who pass meconium in utero.&#xD;
&#xD;
          7. . Babies born with multiple congenital anomalies or abdominal wall defects.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas C Dannaway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Pediatrics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bentley-Lewis R, Levkoff S, Stuebe A, Seely EW. Gestational diabetes mellitus: postpartum opportunities for the diagnosis and prevention of type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2008 Oct;4(10):552-8. doi: 10.1038/ncpendmet0965. Epub 2008 Sep 9. Review.</citation>
    <PMID>18779843</PMID>
  </reference>
  <reference>
    <citation>Bell R, Bailey K, Cresswell T, Hawthorne G, Critchley J, Lewis-Barned N; Northern Diabetic Pregnancy Survey Steering Group. Trends in prevalence and outcomes of pregnancy in women with pre-existing type I and type II diabetes. BJOG. 2008 Mar;115(4):445-52. doi: 10.1111/j.1471-0528.2007.01644.x.</citation>
    <PMID>18271881</PMID>
  </reference>
  <reference>
    <citation>Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care. 2008 May;31(5):899-904. doi: 10.2337/dc07-2345. Epub 2008 Jan 25.</citation>
    <PMID>18223030</PMID>
  </reference>
  <reference>
    <citation>Pichini S, Marchei E, Vagnarelli F, Tarani L, Raimondi F, Maffucci R, Sacher B, Bisceglia M, Rapisardi G, Elicio MR, Biban P, Zuccaro P, Pacifici R, Pierantozzi A, Morini L. Assessment of prenatal exposure to ethanol by meconium analysis: results of an Italian multicenter study. Alcohol Clin Exp Res. 2012 Mar;36(3):417-24. doi: 10.1111/j.1530-0277.2011.01647.x. Epub 2011 Dec 14.</citation>
    <PMID>22168178</PMID>
  </reference>
  <reference>
    <citation>Bearer CF, Jacobson JL, Jacobson SW, Barr D, Croxford J, Molteno CD, Viljoen DL, Marais AS, Chiodo LM, Cwik AS. Validation of a new biomarker of fetal exposure to alcohol. J Pediatr. 2003 Oct;143(4):463-9.</citation>
    <PMID>14571221</PMID>
  </reference>
  <reference>
    <citation>Ostrea EM Jr, Hernandez JD, Bielawski DM, Kan JM, Leonardo GM, Abela MB, Church MW, Hannigan JH, Janisse JJ, Ager JW, Sokol RJ. Fatty acid ethyl esters in meconium: are they biomarkers of fetal alcohol exposure and effect? Alcohol Clin Exp Res. 2006 Jul;30(7):1152-9.</citation>
    <PMID>16792562</PMID>
  </reference>
  <reference>
    <citation>Otasević V, Lazović V, Spalević M, Marinković O. [Endogenous alcohol in patients with diabetes and in patients with severe liver disease]. Med Glas. 1972 Nov;26(11):391-4. Serbian.</citation>
    <PMID>4669769</PMID>
  </reference>
  <reference>
    <citation>Simic M, Ajdukovic N, Veselinovic I, Mitrovic M, Djurendic-Brenesel M. Endogenous ethanol production in patients with diabetes mellitus as a medicolegal problem. Forensic Sci Int. 2012 Mar 10;216(1-3):97-100. doi: 10.1016/j.forsciint.2011.09.003. Epub 2011 Sep 25.</citation>
    <PMID>21945304</PMID>
  </reference>
  <reference>
    <citation>Peterson J, Kirchner HL, Xue W, Minnes S, Singer LT, Bearer CF. Fatty acid ethyl esters in meconium are associated with poorer neurodevelopmental outcomes to two years of age. J Pediatr. 2008 Jun;152(6):788-92. doi: 10.1016/j.jpeds.2007.11.009. Epub 2008 Jan 10.</citation>
    <PMID>18492517</PMID>
  </reference>
  <reference>
    <citation>Gareri J, Lynn H, Handley M, Rao C, Koren G. Prevalence of fetal ethanol exposure in a regional population-based sample by meconium analysis of fatty acid ethyl esters. Ther Drug Monit. 2008 Apr;30(2):239-45. doi: 10.1097/FTD.0b013e318167cfe5.</citation>
    <PMID>18367988</PMID>
  </reference>
  <reference>
    <citation>Zelner I, Shor S, Lynn H, Roukema H, Lum L, Eisinga K, Koren G. Clinical use of meconium fatty acid ethyl esters for identifying children at risk for alcohol-related disabilities: the first reported case. J Popul Ther Clin Pharmacol. 2012;19(1):e26-31. Epub 2012 Jan 10.</citation>
    <PMID>22247425</PMID>
  </reference>
  <reference>
    <citation>Bakhireva LN, Leeman L, Savich RD, Cano S, Gutierrez H, Savage DD, Rayburn WF. The validity of phosphatidylethanol in dried blood spots of newborns for the identification of prenatal alcohol exposure. Alcohol Clin Exp Res. 2014 Apr;38(4):1078-85. doi: 10.1111/acer.12349. Epub 2014 Feb 11.</citation>
    <PMID>24511895</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <results_first_submitted>December 22, 2020</results_first_submitted>
  <results_first_submitted_qc>February 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 21, 2021</results_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gestation</keyword>
  <keyword>diabetes</keyword>
  <keyword>ethanol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Diseases</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT02308735/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).&#xD;
N/A - No intervention</description>
        </group>
        <group group_id="P2">
          <title>A1 IDM</title>
          <description>Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).&#xD;
N/A - No intervention</description>
        </group>
        <group group_id="P3">
          <title>A2 IDM</title>
          <description>Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).&#xD;
N/A - No intervention</description>
        </group>
        <group group_id="P4">
          <title>PGDM - IDM</title>
          <description>Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).&#xD;
N/A - No intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study ended due to lack of funding</population>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).&#xD;
N/A - No intervention</description>
        </group>
        <group group_id="B2">
          <title>A1 IDM</title>
          <description>Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).&#xD;
N/A - No intervention</description>
        </group>
        <group group_id="B3">
          <title>A2 IDM</title>
          <description>Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).&#xD;
N/A - No intervention</description>
        </group>
        <group group_id="B4">
          <title>PGDM - IDM</title>
          <description>Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).&#xD;
N/A - No intervention</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Samples were never sent for analysis due to lack of funding for study.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="1"/>
                    <measurement group_id="B4" value="28.5" spread="4.5"/>
                    <measurement group_id="B5" value="29.8" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Meconium Fatty Acid Ethyl Ester Concentration</title>
        <description>A measure of ethanol metabolites in the meconium of an infant.</description>
        <time_frame>Three months</time_frame>
        <population>This study enrolled four mother/infant dyads but never had results due to low enrollment number</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).&#xD;
N/A - No intervention</description>
          </group>
          <group group_id="O2">
            <title>A1 IDM</title>
            <description>Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).&#xD;
N/A - No intervention</description>
          </group>
          <group group_id="O3">
            <title>A2 IDM</title>
            <description>Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).&#xD;
N/A - No intervention</description>
          </group>
          <group group_id="O4">
            <title>PGDM - IDM</title>
            <description>Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).&#xD;
N/A - No intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Meconium Fatty Acid Ethyl Ester Concentration</title>
          <description>A measure of ethanol metabolites in the meconium of an infant.</description>
          <population>This study enrolled four mother/infant dyads but never had results due to low enrollment number</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phosphatidylethanol Level</title>
        <description>A measure of phosphatidylethanol, an ethanol metabolite, in the cord blood of an infant.</description>
        <time_frame>Three months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected through four months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).&#xD;
N/A - No intervention</description>
        </group>
        <group group_id="E2">
          <title>A1 IDM</title>
          <description>Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).&#xD;
N/A - No intervention</description>
        </group>
        <group group_id="E3">
          <title>A2 IDM</title>
          <description>Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).&#xD;
N/A - No intervention</description>
        </group>
        <group group_id="E4">
          <title>PGDM - IDM</title>
          <description>Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).&#xD;
N/A - No intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Douglas Dannaway</name_or_title>
      <organization>University of Oklahoma Health Sciences Center</organization>
      <phone>405-271-5215 ext 42048</phone>
      <email>douglas-dannaway@ouhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

